Efficacy of phytotherapy for viral respiratory infections with cough in children

Q3 Medicine
N. Geppe, N. Kolosova, S. Shatalina, D.A. Sazanova
{"title":"Efficacy of phytotherapy for viral respiratory infections with cough in children","authors":"N. Geppe, N. Kolosova, S. Shatalina, D.A. Sazanova","doi":"10.20953/1817-7646-2023-2-45-53","DOIUrl":null,"url":null,"abstract":"Medicinal plants have been used for centuries, and in recent years their application has occupied a significant niche due to ongoing clinical research with herbal products developed using phytoneering techniques. Objective. This open-label comparative observational clinical study aimed to evaluate the efficacy of Bronchipret®, a complex herbal medicine with mucoactive and anti-inflammatory effects, for acute respiratory infections (ARIs) accompanied by cough in children compared to Ambroxol. Patients and methods. A total of 60 children aged 2–12 years old (mean age: 4.3 ± 1.6 years) with clinical signs of ARIs and acute bronchitis were examined. All children were divided into two groups: the study group (group 1, n = 35) received Bronchipret® syrup in age-appropriate doses; the comparison group (group 2, n = 25) received Ambroxol syrup in ageappropriate doses. The duration of treatment was 10 days. Clinical manifestations of the disease (temperature, cough, respiratory sounds) were evaluated in points before the beginning of treatment, after 5 and 10 days. Computer bronchophonography (CBPG) was used to assess external respiratory function (ERF). Results. There were no significant differences between the groups at baseline. Both groups showed positive dynamics against the background of treatment. In group 1, 80% of the children (n = 27) had no cough, while 20% (n = 7) had residual cough (0.33 ± 0.1 points) by the 10th day of treatment. In group 2, cough resolved in 64% of the children (n = 16) by day 10 of treatment, and 36% had an occasional wet cough during the day. All children had no nocturnal cough. Computer bronchophonography in both groups revealed normalization of the parameters of acoustic component of the respiratory function (ACRF) in the low-, medium-, and high-frequency ranges, indicating a decrease in inflammation in the respiratory tract. Conclusion. The use of Bronchipret® in acute respiratory infections with cough in children is not inferior in effectiveness to Ambroxol and is well tolerated. Key words: children, acute respiratory infections, cough, phytotherapy, Bronchipret®","PeriodicalId":38157,"journal":{"name":"Voprosy Prakticheskoi Pediatrii","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Voprosy Prakticheskoi Pediatrii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1817-7646-2023-2-45-53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Medicinal plants have been used for centuries, and in recent years their application has occupied a significant niche due to ongoing clinical research with herbal products developed using phytoneering techniques. Objective. This open-label comparative observational clinical study aimed to evaluate the efficacy of Bronchipret®, a complex herbal medicine with mucoactive and anti-inflammatory effects, for acute respiratory infections (ARIs) accompanied by cough in children compared to Ambroxol. Patients and methods. A total of 60 children aged 2–12 years old (mean age: 4.3 ± 1.6 years) with clinical signs of ARIs and acute bronchitis were examined. All children were divided into two groups: the study group (group 1, n = 35) received Bronchipret® syrup in age-appropriate doses; the comparison group (group 2, n = 25) received Ambroxol syrup in ageappropriate doses. The duration of treatment was 10 days. Clinical manifestations of the disease (temperature, cough, respiratory sounds) were evaluated in points before the beginning of treatment, after 5 and 10 days. Computer bronchophonography (CBPG) was used to assess external respiratory function (ERF). Results. There were no significant differences between the groups at baseline. Both groups showed positive dynamics against the background of treatment. In group 1, 80% of the children (n = 27) had no cough, while 20% (n = 7) had residual cough (0.33 ± 0.1 points) by the 10th day of treatment. In group 2, cough resolved in 64% of the children (n = 16) by day 10 of treatment, and 36% had an occasional wet cough during the day. All children had no nocturnal cough. Computer bronchophonography in both groups revealed normalization of the parameters of acoustic component of the respiratory function (ACRF) in the low-, medium-, and high-frequency ranges, indicating a decrease in inflammation in the respiratory tract. Conclusion. The use of Bronchipret® in acute respiratory infections with cough in children is not inferior in effectiveness to Ambroxol and is well tolerated. Key words: children, acute respiratory infections, cough, phytotherapy, Bronchipret®
植物疗法治疗小儿病毒性呼吸道感染并发咳嗽的疗效观察
药用植物已经使用了几个世纪,近年来,由于使用植物工程技术开发的草药产品正在进行临床研究,它们的应用已经占据了一个重要的利基。目标。这项开放标签比较观察性临床研究旨在评估支气管pret®的疗效,支气管pret®是一种具有粘膜活性和抗炎作用的复杂草药,与氨溴索相比,用于治疗儿童急性呼吸道感染(ARIs)伴咳嗽。患者和方法。研究对象为60例2 ~ 12岁,伴有急性呼吸道感染和急性支气管炎临床症状的儿童(平均年龄4.3±1.6岁)。所有儿童被分为两组:研究组(第1组,n = 35)接受与年龄相适应剂量的支pret®糖浆;对照组(2组,n = 25)给予符合年龄剂量的氨溴索糖浆治疗。疗程为10 d。治疗开始前、治疗后5天、治疗后10天分别对患者的临床表现(体温、咳嗽、呼吸音)进行评分。采用计算机支气管造影(CBPG)评估外呼吸功能(ERF)。结果。两组在基线时无显著差异。两组在治疗背景下都表现出积极的动力。第1组治疗第10天,80%患儿(n = 27)无咳嗽,20%患儿(n = 7)有残余咳嗽(0.33±0.1分)。在第2组中,64%的儿童(n = 16)在治疗第10天咳嗽消失,36%的儿童在白天偶尔出现湿咳。所有儿童均无夜间咳嗽。两组患者的计算机支气管造影显示呼吸功能声学成分(ACRF)在低、中、高频范围内的参数正常化,表明呼吸道炎症减轻。结论。支气管pret®治疗儿童急性呼吸道感染伴咳嗽的疗效不逊于氨溴索,且耐受性良好。关键词:儿童;急性呼吸道感染;咳嗽
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Voprosy Prakticheskoi Pediatrii
Voprosy Prakticheskoi Pediatrii Medicine-Pediatrics, Perinatology and Child Health
CiteScore
1.20
自引率
0.00%
发文量
50
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信